|
News
2008 – 2007 – 2006 – 2005
November 27, 2007
Amorfix Discovers Common Link Between ALS and Alzheimer’s Disease
Amorfix today announced the discovery of misfolded superoxide dismutase 1 (SOD1) protein in the brains of people with Alzheimer’s Disease. This breakthrough result suggests that SOD1 is a common link between the two brain-wasting diseases, Alzheimer’s and ALS, also known as Lou Gehrig’s Disease. SOD1 has a “Jekyll-and-Hyde” nature as it normally plays an important protective role in detoxifying free radicals in the body, but when misfolded can create lethal oxidative free radicals. More
November 15, 2007
Update on Brussels CE Mark Workshop
November 13, 2007
Amorfix Announces Second Quarter Fiscal 2008 Results
More
October 25, 2007
Amorfix Test Detects Scrapie Prions in Blood of Scrapie-Infected Sheep
Amorfix Life Sciences today announced the results from the testing of a blinded panel of blood samples from scrapie infected sheep. Amorfix correctly identified 18 out of 20 individual sheep blood samples in a blinded panel provided by an independent third-party laboratory, the Caine Veterinary Teaching Center, University of Idaho. More
View the Brussels workshop presentation.
October 9, 2007
Amorfix Develops Two Vaccines that Extends Life in Amyotrophic Lateral Sclerosis (ALS) Animal Model
Amorfix Life Sciences today announced that it will be presenting the results from its vaccine development program for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig’s disease, at the 132nd Annual Meeting of the American Neurological Association today in Washington, DC. The vaccine approach, also known as active immunization, is the second therapeutic approach for which proof-of-concept has been established by Amorfix for the treatment of ALS this year. In March, Amorfix established a passive immunization approach in the same mouse model of ALS by injecting monoclonal antibodies that target the misfolded superoxide dismutase 1 (SOD1) protein. More
View the poster presentation.
September 20, 2007
Amorfix to Present at Workshop for vCJD Diagnostic Assays Hosted by the European Commission
Amorfix Life Sciences announced today that it has been invited to present at a workshop on the common technical specifications (CTS) for variant Creutzfeldt-Jacob Disease (vCJD) diagnostic assays to be held on October 26 in Brussels, Belgium and sponsored by the Medical Device branch of the Enterprise and Industry Directorate-General of the European Commission. More
August 14, 2007
Amorfix Announces First Quarter Fiscal 2008 Results
More
August 10, 2007
Amorfix Opens the Markets
July 25, 2007
Amorfix Commences Trading on the TSX
Amorfix Life Sciences announced that its common shares have been approved for listing on the Toronto Stock Exchange (TSX) and will no longer trade on the TSX Venture Exchange. Trading on the TSX is expected to commence today, July 25, 2007, under the symbol AMF.
Amorfix was initially listed and began trading on the TSX Venture Exchange on October 3, 2005. More
July 23, 2007
Amorfix to Receive Biogen's First Milestone Payment
Amorfix Life Sciences has received received notice from Biogen Idec (NASDAQ: BIIB) that they will be exercising the first milestone investment under the August 2006 research and investment agreement. The milestone investment allows Biogen Idec to retain its exclusive worldwide option to license Amorfix’s therapeutic candidates for Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. Biogen Idec will subscribe for 91,445 shares of Amorfix at a price of Cdn$1.76 per share for gross proceeds to Amorfix of US$150,000. The shares are subject to a four-month hold period. More
July 17, 2007
Amorfix Receives Approval to List on the Toronto Stock Exchange
Amorfix Life Sciences (TSX-V:AMF) today announced that the common shares of the Company have been conditionally approved for listing on the Toronto Stock Exchange ( TSX). Amorfix is currently listed on the TSX Venture Exchange. More
June 27, 2007
Amorfix Presents vCJD Blood Test Results from its Commercial High-Throughput Platform at Tthe TSE Conference in Berlin
Amorfix Life Sciences today announced that Dr. Neil Cashman, Chief Scientific Officer of Amorfix, presented an overview of the Company’s proprietary Epitope Protection (EP) technology for the in vitro detection of variant Creutzfeldt-Jacob Disease (vCJD) at the Transmissible Spongiform Encephalopathies (TSE) Conference held earlier today in Berlin, Germany. The presentation entitled, “Detection of vCJD prions in blood using epitope protection” highlighted the sensitivity and specificity of the EP-vCJD™ high-throughput diagnostic test for screening blood donations. More
June 15, 2007
Amorfix Receives ISO13485 Certification
Amorfix Life Sciences today announced that it has achieved ISO13485:2003 certification for its in vitro diagnostic EP-vCJDTM test for detection of aggregated misfolded proteins in variant Creutzfeldt-Jacob Disease (vCJD). More
June 11, 2007
Amorfix Announces 2006 Results
More
June 7, 2007
Amorfix Recruits ALS Leader Joseph Beckman to Join Scientific Advisory Board
Amorfix Life Sciences announced today that Joseph Beckman, Ph.D., will join the Company’s Scientific Advisory Board. Dr. Beckman is an expert in Amyotrophic Lateral Sclerosis (ALS) disease and the role of superoxide dismutase-1 (SOD1) in this disease. Amorfix’s therapeutic program for ALS targets SOD1. More
May 7, 2007
Amorfix's ALS Technology Published in Nature Medicine
Amorfix Life Sciences Ltd. announced that in a report published today in the journal Nature Medicine, researchers demonstrated that misfolded superoxide dismutase 1 (SOD1) protein is present in nerve tissue from patients with Amyotrophic Lateral Sclerosis (ALS), commonly referred to as Lou Gehrig's disease. The article outlines the researchers' findings that in animal models, the misfolded SOD1 was found in motor neurons prior to disease symptoms and was correlated to disease progression. More
April 24, 2007
Dr. George Adams Interviewed on BNN's 'The Street - Power Breakfast'
April 2, 2007
Amorifx Reseach Featured in April Edition of CIHR Media E-Newsletter
CIHR start-up ready to launch rapid blood tests for Creutzfeldt-Jakob disease
Amorfix Life Sciences Ltd., Toronto, has developed a rapid screening test that could protect blood supplies from variant Creutzfeldt-Jakob disease (vCJD) - the human form of mad cow disease. Launched with support from CIHR's Proof of Principle program and founded on CIHR-funded research, Amorfix is the first company to develop a technology that can rapidly screen tens of thousands of blood samples to determine how many people have been infected with vCJD and how many people are incubating the disease. Amorfix is also using the technology to develop a diagnostic test for Alzheimer's disease.
March 23, 2007
Amorfix Provides Corporate Update on Therapeutics Program for Amyotrohpic Lateral Sclerosis (ALS or Lou Gehrig's Disease)
Amorfix Life Sciences Ltd. today annouced Dr. Neil Cashman, Chief Scientific Officer of Amorfix will be presenting a study entitled "Immunotherapy of ALS" at the ALS Canada Research Conference in Toronto, on March 25, 2007. This study is based on pioneering work by Dr. Cashman and shows for the first time promising animal studies that a targeted immunotherapy approach may lead to an effective treatment for this debilitating disease. More
March 8, 2007
Amorfix Completes $10.0 Million Private Placement
Amorfix Life Sciences Ltd. today announced it has completed its previously announced private placement, including the entire option granted to the underwriters, by issuing 7,694,000 units at a price of $1.30 per unit for total gross proceed to the Company of approximately $10,000,000. More
February 26, 2007
Amorfix Provides Corporate Update and Announces Private Placement
Amorfix Life Sciences Ltd. today announced a bought deal private placement financing of $8.0 million and provided a corporate update on the development of its proprietary Epitope Protection diagnostic test for variant Creutzfeldt-Jakob Disease (EP-vCJP). More
February 12, 2007
Amorfix to Present vCJD Blood Test Results from Its Commerical Scale High-Throughput Platform at the Cambridge Health Institute Conference
Amorfix Life Sciences Ltd. announced today that it is presenting for the first time results from its Epitope Protection technology, a prototype commercial scale blood test for the diagnosis of variant Creutzfeldt-Jakob Disease, (EP-vCJD) at the Cambridge Health Institute's 11th Annual Conference on TSE Diseases in Baltimore, Maryland. Amorfix's EP-vCJD test is now based on a 96-well high-throughput platform that enables thousands of tests to be performed in a single day. More
January 10, 2007
Amorfix Announces Michael Sonnenreich as a New Director and
Establishment of a Scientific Advisory Board with the Appointment of Dr. Don Cleveland
Amorfix Life Sciences Inc. is pleased to announce the appointment of Mr. Michael Sonnenreich to the Company’s Board of Directors. Amorfix today also announced the formation of a Scientific Advisory Board (SAB) led by Dr. Neil Cashman, Chief Scientific Officer for Amorfix, who will step down from the Board of Directors to Chair the SAB. Joining Dr. Cashman is an internationally distinguished expert in ALS and motor neuron diseases, Dr. Don Cleveland. More
|
